Health Economics of Chemoprevention for breast cancer in Australia: June 2008

01 Jun 2008
Share this page Email this page to a friend Share this page via Twitter Share this page via Facebook Share this page via LinkedIn

Chemoprevention with raloxifene and tamoxifen can help avoid breast cancer in about 9,000 high-risk women in Australia.

This report assesses the economic impact of the introduction of raloxifene and/or tamoxifen to prevent breast cancer in Australia. The report models the cost-effectiveness of both drugs when used as chemopreventive agents compared with no treatment. 

Top of page